Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Orforglipron, a small-molecule, nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, is being investigated as a treatment for obesity. METHODS: In this phase 3, multinational, randomized, double-blind trial, we examined the safety and efficacy of once-daily orforglipron at doses of 6 mg, 12 mg, or 36 mg, as compared with placebo (assigned in a 3:3:3:4 ratio) as an adjunct to healthy diet and physical activity for 72 weeks. All the patients had obesity without diabetes mellitus. The primary end point was the percent change in body weight from baseline to week 72, as assessed according to the treatment-regimen estimand in the intention-to-treat population. RESULTS: A total of 3127 patients underwent randomization. The mean change in body weight from baseline to week 72 was -7.5% (95% confidence interval [CI], -8.2 to -6.8) with 6 mg of orforglipron, -8.4% (95% CI, -9.1 to -7.7) with 12 mg of orforglipron, and -11.2% (95% CI, -12.0 to -10.4) with 36 mg of orforglipron, as compared with -2.1% (95% CI, -2.8 to -1.4) with placebo (P<0.001 for all comparisons with placebo). Among the patients in the orforglipron 36-mg group, 54.6% had a reduction of 10% or more, 36.0% had a reduction of 15% or more, and 18.4% had a reduction of 20% or more, as compared with 12.9%, 5.9%, and 2.8% of the patients, respectively, in the placebo group. Waist circumference, systolic blood pressure, triglyceride levels, and non-HDL cholesterol levels significantly improved with orforglipron treatment as compared with placebo. Adverse events resulted in treatment discontinuation in 5.3 to 10.3% of the patients in the orforglipron groups and in 2.7% of those in the placebo group. The most common adverse events with orforglipron were gastrointestinal effects, which were mostly mild to moderate. CONCLUSIONS: In adults with obesity, 72-week treatment with orforglipron led to significantly greater reductions in body weight than placebo; the adverse-event profile was consistent with that of other GLP-1 receptor agonists. (Funded by Eli Lilly; ATTAIN-1 ClinicalTrials.gov number, NCT05869903.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In adults with overweight or obesity, plus at least one weight-related coexisting condition, but without type 2 diabetes, the maximum reduction in weight at week 72 was 11•2% with orforglipron 36 mg/day versus 2•1 % with placebo.130”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [130]
In the citing paper
“Orforglipron 6-36 mg once daily vs placebo over 72 weeks Up to 9•1% (8•1-10•1) Up to 0•3% (several doses; SEM 0•0%) High drug discontinuation rate (up to 24%), up to 7% due to gastrointestinal adverse events; weight plateau reached after ~52 weeks Wharton et al (2025) 130”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [130]
In the citing paper
“Notably, a substantial proportion of participants achieved ≥10% weight loss, a threshold associated with meaningful metabolic improvements and cardiovascular risk reduction.”
From Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes (2026) · cites this paper as [46]
In the citing paper
“Across both trials, orforglipron produced significant, sustained weight reductions over 72 weeks, with the highest dose yielding mean body weight loss of 12–15% in non-diabetic participants and 10–12% in T2D populations [25,30,46,47].”
From Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes (2026) · cites this paper as [46]
In the citing paper
“In the phase 3 ATTAIN-1 trial, it produced up to 11.2% WL with the highest dose of 36 mg daily in individuals without T2DM [142].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [142]
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Definition and diagnostic criteria of clinical obesity
Rubino, F., Cummings, D. E., Eckel, R. H., Cohen, R. V., Wilding, J. P. H., Brown, W. A., Stanford, F. C., Batterham, R. L., Farooqi, I. S., Farpour-Lambert, N. J., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00316-4 · Cited by 1,811
Self-citationWeight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over
Ryan, D. H., & Yockey, S. R. (2017) · Current Obesity Reports · doi:10.1007/s13679-017-0262-y · Cited by 831
(2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30162-0 · Cited by 738
A new framework for the diagnosis, staging and management of obesity in adults
Busetto, L., Dicker, D., Frühbeck, G., Halford, J. C. G., Sbraccia, P., Yumuk, V., & Goossens, G. H. (2024) · Nature Medicine · doi:10.1038/s41591-024-03095-3 · Cited by 501
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Wharton, S., Blevins, T., Connery, L., Rosenstock, J., Raha, S., Liu, R., Ma, X., Mather, K. J., Haupt, A., Robins, D., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2302392 · Cited by 478
Self-citationKnop, F. K., Aroda, V. R., do Vale, R. D., Holst-Hansen, T., Laursen, P. N., Rosenstock, J., Rubino, D. M., & Garvey, W. T. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01185-6 · Cited by 431
A graphical approach to sequentially rejective multiple test procedures
Bretz, F., Maurer, W., Brannath, W., & Posch, M. (2009) · Statistics in Medicine · doi:10.1002/sim.3495 · Cited by 420
Research works printed but not linked: 2
- Wu Q, Du Y, Ahmad N, et al. Sex differences in body weight reduction achieved with incretin-based therapies: a meta-analysis. Poster abstracts. Obesity (Silver Spring) 2024;32:Suppl 1:5-308.39562472
- Pfizer provides update on oral GLP-1 receptor agonist danuglipron. News release of Pfizer New York April 14 2025 (https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-update-oral-glp-1-receptor-agonist).
Cited by
Celletti, F., Farrar, J., & De Regil, L. (2026) · JAMA · doi:10.1001/jama.2025.24288 · Cited by 153
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Horn, D. B., Ryan, D. H., Kis, S. G., Alves, B., Mu, Y., Kim, S. G., Aberle, J., Bain, S. C., Allen, S., Sarker, E., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02165-8 · Cited by 70
Self-citationBillings, L. K., Hsia, S. H., Bays, H. E., Tidemann‐Miller, B., O’Hagan, J., Tham, L. S., Butler, A., KAZDA, C. M., Mather, K. J., & Coşkun, T. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02155-5 · Cited by 47
Rosenstock, J., Yabe, D., Cox, D., Li, J., Denning, M., Wu, W.-S., Liu, R., Zhao, Y., Manghi, F. P., Abalos, F., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00202-3 · Cited by 49
Kansakar, U., Jankauskas, S. S., Pande, S., Mone, P., Varzideh, F., & Santulli, G. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031409 · Cited by 22
Aronne, L. J., Horn, D. B., le Roux, C. W., Chao, A. M., Ho, W., Halpern, B., Griffin, R., Xie, C., Valderas, E. G., Lee, C. J., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04386-7 · Cited by 22
“Consistent with the orforglipron clinical trial program demonstrating an efficacy and safety profile generally similar to injectable GLP-1 RAs, orforglipron maintained nearly all the weight loss achieved on injectable semaglutide 9,14 .”
Self-citationBarana, L., De Fano, M., Cavallo, M., Manco, M., Prete, D., Fanelli, C. G., Porcellati, F., & Pippi, R. (2025) · Nutrients · doi:10.3390/nu18010131 · Cited by 13
Dietary restriction in aging and longevity
Schmauck‐Medina, T., Lautrup, S., Francesco, A. D., Mitchell, S. J., Clemmensen, C., Partridge, L., Roth, G. S., Anderson, R. M., Mattison, J. A., de Cabo, R., et al. (2026) · Nature Aging · doi:10.1038/s43587-026-01091-5 · Cited by 26
Ma, X., Li, Y. G., Raha, S., Sperry, D. C., Coutant, D. E., & Bhattachar, S. (2026) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70783 · Cited by 13
The evolving landscape of obesity pharmacotherapy
Petersen, J., Finan, B., Johansen, V. B. I., Müller, T. D., & Clemmensen, C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01427-1 · Cited by 19
Pandey, R. K., Jan, M., Mohammad, A., Jawaid, K. A., Naveed, M., Abid, M. A., Amir, A. B., Ahmed, S., Safiullah, M., Bhatti, M. I., et al. (2025) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.70134 · Cited by 9
From needles to pills: oral GLP-1 therapy enters the obesity arena
Santulli, G. (2025) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-025-00245-5 · Cited by 12
Miramontes‐González, J. P., Rodrigo-Alaíz, Á., Gabella-Martín, M., Calle, D. G., Carretero-Gómez, J., & Corral-Gudino, L. (2026) · Diabetes Therapy · doi:10.1007/s13300-025-01829-1 · Cited by 11
Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies
Alhazmi, A., & le Roux, C. W. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1788698 · Cited by 10
Patil, S., Jha, N., & Jha, M. K. (2026) · Addictive Behaviors Reports · doi:10.1016/j.abrep.2026.100671 · Cited by 24
Oral small-molecule GLP-1 receptor agonist for type 2 diabetes and obesity
Chow, E. W.-K., & Chow, E. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02381-5 · Cited by 7
Alper, A., Peleg, G., Fagin, A., Shah, P. P., Chowdhury, I. Z., Gonzales, A., & FAILLACE, R. T. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-025-00270-4 · Cited by 7
Tantoush, M., Almaghrabi, Y., Abusbaeh, A., Ahmed, N., Tantush, A., Hamida, B. B., Sagher, M., Sager, M., Abouslima, A., Elbahnasawy, S. E., et al. (2026) · Cureus · doi:10.7759/cureus.102018 · Cited by 7
Ho, M. J., Liew, C. F., Tan, N. A. M. R., Morita, A., & Oon, H. H. B. (2026) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2026.2665732 · Cited by 7
CVOT Summit Report 2025: advances along the cardiovascular–kidney–metabolic disease continuum
Schnell, O., Agarwal, A., Azizi, M., Ballwieser, D. A., Barnard-Kelly, K. D., Battelino, T., Blüher, M., Bugianesi, E., Cebrián, A., Ceriello, A., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03140-0 · Cited by 6
Self-citationPill version of obesity jab is approved in US, with UK decision pending
Dyer, O. (2026) · BMJ · doi:10.1136/bmj.s2 · Cited by 5
Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes
Pillai, A. A., Sharma, A. M., Krayem, H., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001139 · Cited by 3
Jamal, A., Khan, S., Qadri, M., Shah, A., Iftikhar, H., Fatima, E., Ahmad, M., Sikandar, M., Jawed, I., Muneeb, M., et al. (2026) · Acta Diabetologica · doi:10.1007/s00592-025-02635-8 · Cited by 3
Hammad, N., Ramadan, A. M., Nazmy, A., Elazab, A., & Abdelaziz, A. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261420404 · Cited by 4
Welch, M., Forst, T. M., Jia, W., del Pino, P. O., Denning, M., Wu, W.-S., Li, J., Liu, R., EIFU, M., Chen, Y., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00800-7 · Cited by 7
Glucagon‐Like Peptide‐1 Receptor Agonist‐Based Agents and Body Composition: Filling More Gaps
Dubin, R. L., Sanders, T. N., Schwab, H. M., Heymsfield, S. B., & Greenway, F. L. (2026) · Obesity · doi:10.1002/oby.70212 · Cited by 3
ROSENSTOCK, J., Lingvay, I., RYAN, D. H., Jastreboff, A. M., Kushner, R., ACOSTA, A., Blevins, T., Choi, M., HOLMES, F. L., Smith, T., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04476-6 · Cited by 9
Advances in incretin-based drug discovery in 2025
Müller, T. D. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01219-4 · Cited by 4
GLP-1 receptor agonists in asthma: targeting metabolic-inflammatory crossroads
O’Brien, H., Franciosi, A. N., & Butler, M. W. (2026) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001249 · Cited by 3
Chen, F., Dall, T. M., Ferguson, C. C., Sapra, T., Hafida, S., Livingston, T., ElSayed, N. A., Moody, A., & Bannuru, R. R. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doci25-0004 · Cited by 2
Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives
Fu, L., Ding, R., Xu, G., Hu, J., & Yang, P. C. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156594 · Cited by 6
GLP ‐1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta‐Analysis of RCTs
Vienghirun, J., Sawangjit, R., Suttiruksa, S., Chaiyakunapruk, N., Jinathongthai, P., Khunti, K., & Lee, S. W. H. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70698 · Cited by 4
Hageen, A. W., Gadelmawla, A. F., Saleh, A. O., Abdallfatah, A., Reyad, M., El‐Nemr, A. F., Maihoub, O., Elsekhary, A., Eladawi, S., Ayalew, B. D., et al. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70222 · Cited by 3
Cardiovascular Risk Reduction With GLP-1 RA Drugs
Pigeyre, M., & Gerstein, H. C. (2026) · Circulation · doi:10.1161/circulationaha.126.079319 · Cited by 4
Kamrul-Hasan, A. B. M., Dutta, D., Mahajan, K., Nagendra, L., Pappachan, J. M., Bhattacharya, S., & Kalra, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70922 · Cited by 2
Michalak, W., Bøg, M., Bendixen, T., Chowdhury, R., Cowley, P., Laugesen, C., Rathor, N., & Kushner, R. F. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70919 · Cited by 4
Khachaturov, M., & Goulis, D. G. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70822 · Cited by 3
Wharton, S., Stefański, A., Chen, J., Rao, G. S., Twum, E. A., & Denning, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71032 · Cited by 3
Self-citationAhmad, Y., Wasan, R., Perchik, J. D., & Nanda, N. C. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15124430 · Cited by 2
Mora, P., Aroda, V. R., Asong, M., Blüher, M., Carlander, A. F., Kaltoft, M., Vilsen, L. N., & Rosenstock, J. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01247-x · Cited by 4
Discontinuation of incretin-based therapies in obesity: the complexity of a breakup
Avogaro, A., & Fadini, G. P. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.106833 · Cited by 6
Li, Y., Sheng, H., Zhou, T., Xing, C., Kukasch, M., Shao, S., Youhanna, S. C., Vorrink, S. U., Liang, Y., Nies, A. T., et al. (2026) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2026.100346 · Cited by 3
Zaman, W., & Amin, A. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2676109 · Cited by 2
Hurka, K. L., Movva, A. K., Sunkara, A., Kalala, S., Sohn, M., Mitra, K., & Anastasio, A. T. (2026) · Diabetology · doi:10.3390/diabetology7030054 · Cited by 2
A new era in reducing obesity and the risk of cardiovascular disease events in preeclampsia
Malik, A., & Malik, R. A. (2026) · Journal of Hypertension · doi:10.1097/hjh.0000000000004250 · Cited by 1
Shirley, M. (2026) · Drugs · doi:10.1007/s40265-026-02363-5 · Cited by 3
Is Placebo Still Ethical in Trials of Incretin Therapies?
Neuen, B. L., Ostrominski, J. W., & Vaduganathan, M. (2026) · Circulation · doi:10.1161/circulationaha.125.077277 · Cited by 1
Oral Glucagon-Like Peptide-1 Receptor Agonists for Preventing Cardiorenal Complications
Odeleye, V., Singh, N., Gautam, S., Shannon, E., Bibb, W. M., McClure, M., & Paul, T. K. (2026) · Current Cardiology Reports · doi:10.1007/s11886-026-02357-5 · Cited by 1
Alper, A., Fagin, A., Karthikeyan, A., Karp, A., Terashima, R., Murli, H., Gershon, A., & FAILLACE, R. T. (2026) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-026-00814-4 · Cited by 1
Morse, B. L., Coutant, D. E., Ma, X., Raha, S., Aithal, K., Nicoll, C., Rougée, L. R. A., & Bhattachar, S. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70377 · Cited by 4
Bellido, V., le Roux, C. W., Ekinci, E. I., Bjornstad, P., Frías, J. P., Giblin, K. A., Eyde, S., Park, S. Y., Ferro, J., Johnson, C., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01861-1 · Cited by 8
Curto, R., Giglione, C., Cannarella, R., Berisha, H., Hattab, R., Condorelli, R. A., Vignera, S. L., Calogero, A. E., & Magni, P. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108278 · Cited by 2
Medical treatments for obesity: what does the future have in store?
Bassatne, A., & Rizo, I. M. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag274 · Cited by 1
Malhotra, A., Gottlieb, D. J., Kundel, V., Woehrle, H., Chakladar, S., GONCALVES, L. F., & Calamai, G. (2026) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2026.101660 · Cited by 2
One small molecule for man, one giant leap for mankind with obesity
Novikoff, A., & Müller, T. D. (2025) · Med · doi:10.1016/j.medj.2025.100924 · Cited by 1
GLP-1 receptor agonists and their implications for female reproductive health
Eagles, E., Simpson, B., Makajeva, J., et al. (2026) · Case Reports in Women s Health · doi:10.1016/j.crwh.2026.e00812 · Cited by 1
Braha, A., Timar, B., Sturza, A., & Timar, R. Z. (2026) · Medicina · doi:10.3390/medicina62081509 · Cited by 2
Glucagon-like peptide-1–based pharmacological treatment of obesity: a narrative review
Son, J. W. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0138 · Cited by 1
Davies, M. J., Aroda, V. R., Rosenstock, J., Capehorn, M., Pedersen, S. D., Morizzo, E., Sonali, M., Johansson, P. A., Grice, D., Andersson, A., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00748-8 · Cited by 3
Horn, D. B., Shukla, A. P., Huang, H., Twum, E. A., Allen, S. E., & Kiš, S. G. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100301 · Cited by 2
Self-citationOvergaard, R. V., Agersø, H., Hollensen, C., Rathor, N., & Bomberg, E. M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71030 · Cited by 1
Thomas, P. E., Nielsen, S. F., Nordestgaard, B. G., & Kamstrup, P. R. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag106 · Cited by 1
Guo, J., Bachor, T. P., Takahashi, R., Steffek, M., Fitzgerald, G. A., Huffman, B. J., Braun, D., Han, S. J., Sandmann, T., Ha, C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.06.680810 · Cited by 2
Li, M., Fang, J., Qi, G., Guo, S., Xu, T., Lu, Y., Yuan, Q., Wang, J., Zhu, S., Shen, J., et al. (2026) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6c00077 · Cited by 3
Alhazmi, A., & le Roux, C. W. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71074 · Cited by 1
Lista, S., Ballerio, M., López‐Ortiz, S., Khoramipour, K., Imbimbo, B. P., Santos‐Lozano, A., Minoretti, P., & Emanuele, E. (2026) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2026.174217 · Cited by 1
Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review
Laroche, M., Geniaux, H., & Jardou, M. (2026) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-026-04079-7 · Cited by 9
Li, Y., Glotfelty, E. J., Parekh, P., Batsaikhan, B., Luo, W., Jackson, S. N., Harvey, B. K., & Greig, N. H. (2026) · Cells · doi:10.3390/cells15141301 · Cited by 2
Barbosa, L. A. D. S., Almarie, B., Toledo‐Silva, G., & Moreira, E. L. G. (2026) · World Patent Information · doi:10.1016/j.wpi.2026.102488
Marassi, M., Pollis, R. M., & Fadini, G. P. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104714
Orforglipron: An Oral GLP-1 Receptor Agonist for Obesity Treatment
Wietholter, J. P., & Terpening, C. M. (2026) · Annals of Pharmacotherapy · doi:10.1177/10600280261486055
Hepatic steatosis: A pandemic disease causing serious secondary diseases
Canbay, A., Figge, A., Patsalis, P., Baars, T., Özcürümez, M. K., & Götze, O. (2026) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2026.0074
DeCoster, M., & Narla, S. (2026) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2026.09.003 · Cited by 1
Obesity and Cardiovascular Diseases: CVIA State-of-the-Art Review
Liu, N., Pan, Y., Liu, F., Mei, J., Zhang, X., Zhang, R., Zhang, S., Luo, F., Wu, Y., Gong, Y., et al. (2026) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2026.0010
Treatment potential of oral small-molecule GLP-1 receptor agonists
Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01135-9
Barton, K. I., Boyle, R. J., Dennis, D. A., & Jennings, J. M. (2026) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-25-00892
Oral Incretin-Based Therapies for Weight Management
Cheng, H. E., Bonafede, M., & Shukla, A. P. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01456-6
Self-citationPeptidomimetics in GPCRs: From structural insights to clinical blockbusters
Li, G., Zhou, Q., & Wang, M. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.09.010 · Cited by 1
Rajan, K., Jutley, A., Holliday, M. W., & Navaneethan, S. D. (2026) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s522424
Kenkishvili, A. S., Arutyunyan, M. E., & Maksimov, M. L. (2026) · Spravočnik vrača obŝej praktiki (Journal of Family Medicine) · doi:10.33920/med-10-2607-07
Mehetre, K. N., & Dawane, J. S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1933913
Metabolic Syndrome: From Mechanisms to Therapeutic Interventions
Yan, M., & Xiang, Q. (2026) · MedComm · doi:10.1002/mco2.70934
Han, Y., Shon, J., & Park, Y. J. (2026) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2026.2728313
The evolution of obesity pharmacotherapy from sympathomimetics to incretin-based therapies
Ncube, K. N., Moloi, N., & Malange, T. D. (2026) · SA pharmaceutical journal. · doi:10.36303/sapj.4108 · Cited by 1
Beyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists
Rabbani, S. A., El-Tanani, M., Matalka, I. I., & Rizzo, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1902185
Hat die inkretinbasierte Hypertoniebehandlung eine Zukunft?
Zidek, W. (2026) · CardioVasc · doi:10.1007/s15027-025-3944-5
Can weight-loss pills replace injectables? What the science says
Lenharo, M. (2026) · Nature · doi:10.1038/d41586-026-00856-7
Almandoz, J. P., Tchang, B. G., Myers, K., Traina, A., Bhavsar, J., Divino, V. M., Kent, C., & Tadesse-Bell, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71318
Alhazmi, A., & le Roux, C. W. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2731087
Liu, C., Hui, Q., Linchangco, G. V., Dabbs‐Brown, A., Zhou, J. J., Joseph, J., Reaven, P. D., Rhee, M. K., Djoussé, L., Cho, K., et al. (2026) · medRxiv · doi:10.64898/2026.04.10.26350615
The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms
Davies, I., Holst, J. J., ROSENKILDE, M. M., & Tan, T. (2026) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-061824-043740 · Cited by 3
A rationally designed 18-amino acid peptide with potential as GLP-1 receptor agonist
Singh, A., Shadangi, S., & Rana, S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1789257
Homma, G. (2026) · Pharmaceutical Statistics · doi:10.1002/pst.70111
Mohammad, A., DASHTI, M. H., Malik, M. Z., Rajan, R., & Al‐Mulla, F. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.153525
Dietary Interventions for Hypertriglyceridemia
Kirkpatrick, C. F., Petersen, K. S., Kris-Etherton, P. M., & Maki, K. C. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01444-w
Update in Outpatient General Internal Medicine: Practice-Changing Evidence Published in 2025
Andersen, C. A., Wieland, M. L., Bornstein, S. L., Huber, J. M., Sytsma, T. T., Bhuiyan, M. N., & Wingo, M. T. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.02.048
Ji, L., Gao, L., Li, B., Liu, M., Zhang, X., & Meng, C. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02859-2
Metadata
- Authors
- Wharton, S., Aronne, L. J., Stefanski, A., Alfaris, N. F., Ciudin, A., Yokote, K., Halpern, B., Shukla, A. P., Zhou, C., Macpherson, L., Allen, S. E., Ahmad, N. N., & Klise, S. R.
- Affiliations
- York University (CA)
- Weill Cornell Medicine (US)
- Eli Lilly, Indianapolis
- King Fahd Medical City (SA)
- Universitat Autònoma de Barcelona (ES)
- Chiba University (JP)
- Obesity Center, Nove de Julho Hospital, São Paulo
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-11-06
- Volume
- 393
- Issue
- 18
- Pages
- 1796-1806
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4414222945
- Semantic Scholar
- 55f79ec956543eaa7356b0d7489de3768b213da0
- Cited by
- 189
- References
- 22
- Citations by year
- 2026: 177 · 2025: 12
- FWCI
- 106.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- orforglipron, GLP-1 receptor agonists, obesity treatment, weight loss, waist circumference, blood pressure, lipid profile, gastrointestinal adverse effects, drug safety, dose comparison, non-diabetic obesity, treatment discontinuation, serious adverse events
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Administration, Oral, Adult, Double-Blind Method, Female, Gastrointestinal Diseases, Humans, Male, Middle Aged, Obesity, Oxadiazoles, Weight Loss, Treatment Outcome, Fluorine Compounds, Anti-Obesity Agents, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.